EYEPOINT PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.5 USD | -16.43% |
|
-23.55% | -24.28% |
| Apr. 02 | EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board | CI |
| Mar. 18 | EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index | CI |
Chart calendar EyePoint Pharmaceuticals, Inc.
1b9e18c22f830a9283ad86751b.OThibSDdvOQpkiTEGGsuQRy-3vCO5u5csXEWYkUGFR8.VEpVCW6QzdwZ02GPawd5I03WjL32ub0P8AJ1EHZOY1VKbFpaEKSI0h72ZQ~6730064feb25b57f73a5fd11cef86a7c
Upcoming events on EyePoint Pharmaceuticals, Inc.
Past events on EyePoint Pharmaceuticals, Inc.
| 2024-03-13 09:15 am | Guggenheim Healthy Altitudes Summit |
| 2024-03-10 | Leerink Partners Global Biopharma Conference |
| 2024-03-07 08:30 am | Q4 2023 Earnings Call |
| 2024-03-07 07:00 am | Q4 2023 Earnings Release |
| 2024-03-05 10:30 am | TD Cowen Health Care Conference |
| 2024-02-07 12:30 pm | Guggenheim Healthcare Talks Biotechnology Conference - Fireside Chat |
| 2024-01-10 01:30 pm | JPMorgan Healthcare Conference |
| 2023-12-04 08:00 am | DAVIO 2 Phase 2- Trial Results Call |
| 2023-11-09 08:00 am | Investor Meeting - Key Opinion Leader |
| 2023-11-07 02:30 pm | Guggenheim Securities Inflammation & Immunology Conference |
| 2023-11-03 11:00 am | American Academy Of Ophthalmology Meeting |
| 2023-11-02 11:10 am | Eyecelerator Conference - Panel |
| 2023-11-01 08:30 am | Q3 2023 Earnings Call |
| 2023-11-01 07:00 am | Q3 2023 Earnings Release |
| 2023-10-10 01:45 pm | JonesTrading Healthcare Summit |
| 2023-09-26 12:25 pm | Cantor Global Healthcare Conference - Fireside Chat |
| 2023-09-13 12:50 pm | Baird Global Healthcare Conference - Fireside Chat |
| 2023-09-11 07:00 am | H.C. Wainwright Global Investment Conference |
| 2023-09-05 | Citi BioPharma Conference |
| 2023-08-16 11:00 am | H.C. Wainwright Ophthalmology Virtual Conference - Panel |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 20,4 19,0 7.33% | 34,4 45,6 -24.47% | 36,9 35,2 4.97% | 41,4 41,3 0.31% | 46,0 40,5 13.59% | 47,1 |
|
EBITDA Million USD | Released Forecast Spread | -40,7 -44,8 9.26% | -34,6 -15,0 -130.94% | 0,00 0,00 - | 0,00 0,00 - | 0,00 119 - | 160 |
|
EBIT Million USD | Released Forecast Spread | -47,9 -50,0 4.32% | -37,3 -24,7 -50.96% | -55,3 -52,0 -6.31% | -78,9 -78,6 -0.46% | -75,1 -81,3 7.63% | -89,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -56,8 -59,0 3.82% | -45,4 -36,3 -25.05% | -58,4 -55,2 -5.91% | -102 -82,2 -24.42% | -70,7 -76,6 7.69% | -76,0 |
|
Net income Million USD | Released Forecast Spread | -56,8 -59,0 3.82% | -45,4 -36,3 -25.05% | -58,4 -55,2 -5.91% | -102 -82,2 -24.42% | -70,8 -76,6 7.56% | -79,0 |
|
EPS USD | Released Forecast Spread | -5,40 -5,65 4.42% | -3,54 -2,13 -66.04% | -2,03 -1,99 -2.27% | -2,74 -2,19 -25.23% | -1,82 -1,92 5.4% | -1,53 |
| Announcement Date | 05/03/20 | 04/03/21 | 03/03/22 | 02/03/23 | 07/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 11,5 9,79 17.9% | 9,29 9,89 -6% | 11,6 10,9 6.45% | 10,0 10,9 -8.32% | 10,5 10,4 1.25% | 7,68 7,57 1.54% | 9,11 42,1 -78.39% | 15,2 7,43 104.6% | 14,0 8,70 61.18% | 8,93 | 8,79 | 9,31 | 8,23 |
|
EBITDA Million USD | Released Forecast Spread | 31,0 | 33,0 | 37,0 | 42,0 | 47,0 | ||||||||
|
EBIT Million USD | Released Forecast Spread | -18,1 -14,8 -22.07% | -18,3 -18,5 1.14% | -19,2 -18,8 -2.3% | -18,4 -25,4 27.51% | -23,0 -22,6 -1.95% | -21,6 -25,2 14.42% | -22,8 4,77 -577.27% | -14,4 -20,1 28.26% | -16,4 -22,3 26.68% | -21,5 | -23,2 | -26,0 | -29,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -19,4 -16,2 -20.21% | -21,0 -19,3 -8.59% | -19,4 -19,1 -1.84% | -18,4 -25,2 26.95% | -43,5 -23,4 -85.83% | -21,2 -25,9 18.43% | -22,9 12,4 -284.93% | -12,6 -18,7 32.43% | -14,0 -19,9 29.44% | -18,4 | -20,2 | -23,0 | -26,2 |
|
Net income Million USD | Released Forecast Spread | -19,4 -16,2 -20.21% | -21,0 -19,3 -8.59% | -19,4 -19,1 -1.84% | -18,4 -25,2 26.95% | -43,5 -23,4 -85.83% | -21,2 -25,9 18.43% | -22,9 12,4 -284.93% | -12,6 -18,7 32.43% | -14,1 -19,9 29.03% | -18,4 | -20,2 | -23,0 | -26,2 |
|
EPS USD | Released Forecast Spread | -0,59 -0,56 -5.83% | -0,56 -0,56 0% | -0,52 -0,51 -1.96% | -0,49 -0,65 25.08% | -1,16 -0,62 -88.31% | -0,56 -0,69 18.45% | -0,61 0,57 -207.02% | -0,33 -0,48 31.72% | -0,33 -0,49 32.26% | -0,36 | -0,40 | -0,45 | -0,55 |
| Announcement Date | 03/03/22 | 04/05/22 | 03/08/22 | 02/11/22 | 02/03/23 | 03/05/23 | 02/08/23 | 01/11/23 | 07/03/24 | - | - | - | - |
More events
Past sector events for EyePoint Pharmaceuticals, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- EYPT Stock
- Calendar EyePoint Pharmaceuticals, Inc.
